๋ค์ค์คํฐ๊ทธ๋ฏผ
**๋ค์ค์คํฐ๊ทธ๋ฏผ**์ ๊ฐ์ญ์ ์์ธํธ์ฝ๋ฆฐ์์คํ ๋ผ์ ์ต์ ์ ๋ก, ์์ํ์์๋ ์ฃผ๋ก **์ค์ฆ ๊ทผ๋ฌด๋ ฅ์ฆ**์ ์ง๋จ ๋ฐ ๊ด๋ฆฌ, ๊ทธ๋ฆฌ๊ณ ๋นํ๋ถ๊ทน์ฑ ์ ๊ฒฝ๊ทผ ์ฐจ๋จ์ ์ ํจ๊ณผ๋ฅผ ๊ธธํญํ๋ ๋ฐ ์ฌ์ฉ๋ฉ๋๋ค. ๊ทน์ฑ ๊ตฌ์กฐ๋ฅผ ๊ฐ์ง๊ณ ์์ด ์ค์ถ์ ๊ฒฝ๊ณ(CNS)๋ก์ ํฌ๊ณผ์ฑ์ด ๋ฎ์ต๋๋ค. > **์์ ๊ฒฝ๊ณ :** ํฌ์ฌ ์ ์๋ช ์ ์ํํ๋ **์ฝ๋ฆฐ์ฑ ์๊ธฐ**๋ฅผ ์ ๋ฐํ ์ ์์ต๋๋ค. ์ฌ๊ฐํ ๋ฌด์ค์นด๋ฆฐ์ฑ ๋ถ์์ฉ(์: ์ฌํ ์๋งฅ, ์ฌ์ ์ง, ๊ธฐ๊ด์ง ์์ถ)์ ์กฐ์ ํ๊ธฐ ์ํด ๊ธ๋ฆฌ์ฝํผ๋ก๋๊ณผ์ ๋ณตํฉ์ ๋ฅผ ์ฌ์ฉํ๊ฑฐ๋ ์ฆ๊ฐ์ ์ธ ์ ๋งฅ ํฌ์ฌ๋ฅผ ์ํด ์ํธ๋กํ์ ์ค๋นํด ๋๋ ๊ฒ์ด ๊ฐ๋ ฅํ ๊ถ์ฅ๋ฉ๋๋ค.
์์ฉ ๊ธฐ์ : Neostigmine acts as a reversible inhibitor of the enzyme **acetylcholinesterase** at the neuromuscular junction (NMJ) and autonomic synapses. Inhibition of **acetylcholinesterase** โ Decreased breakdown of **acetylcholine (ACh)** โ Accumulation of ACh in the synaptic cleft โ Prolonged and enhanced stimulation of **nicotinic** and **muscarinic receptors** โ Improved muscle contraction (in myasthenia gravis) and reversal of non-depolarizing neuromuscular blockade.
๋๋ฌผ ์ข ๋ณ ์ฉ๋
- Diagnosis of myasthenia gravis / Antagonism of non-depolarizing neuromuscular block ยท 0.05 mg total dose (historical) ยท IV ยท Single dose ยท N/A ยท Historical dose; recent reports indicate this can cause cholinergic crisis. Recommended to use combined formulation with glycopyrronium. Pre-treat with atropine if using for MG diagnosis.
- Diagnosis of myasthenia gravis / Antagonism of non-depolarizing neuromuscular block ยท 0.05 mg total dose (historical) ยท IV ยท Single dose ยท N/A ยท Extrapolated from general text. Extreme caution due to risk of feline asthma exacerbation.
์ฉ๋์ ๋ฉดํ ์์ ์ ๋ฌธ๊ฐ๋ฅผ ์ํ ์์ ์ฐธ๊ณ ์๋ฃ์ ๋๋ค. ํญ์ ์ต์ ๋ผ๋ฒจ๊ณผ ๊ฐ๋ณ ํ์์ ๋ํด ํ์ธํ์ญ์์ค.
ํฌ์ฌ ๊ฒฝ๋ก
๊ธ๊ธฐ
- Mechanical gastrointestinal obstruction
- Mechanical urinary tract obstruction
- Peritonitis
์ด์๋ฐ์
- Nausea and vomiting
- Increased salivation (ptyalism)
- Diarrhoea
- Muscle fasciculations and cramps
- Weakness and paralysis (with overdose)
- Severe bradyarrhythmias or asystole
- Miosis and nystagmus
- Hypotension
- Bronchoconstriction and increased bronchial secretions
์ฝ๋ฌผ ์ํธ์์ฉ
- Aminoglycosides ยท May antagonize the neuromuscular effects of neostigmine ยท moderate
- Clindamycin ยท May antagonize the neuromuscular effects of neostigmine ยท moderate
- Halogenated inhalational anaesthetics ยท May antagonize the neuromuscular effects of neostigmine ยท moderate
- Quinine and related compounds ยท May increase clinical severity of myasthenia gravis and reduce neostigmine effectiveness ยท moderate
- Beta-blockers ยท May reduce effectiveness in myasthenia gravis; concurrent use may result in severe bradycardia ยท major
- Suxamethonium ยท Neostigmine inhibits its metabolism, prolonging and enhancing its clinical effect (combined use not recommended) ยท major
- Non-depolarizing muscle relaxants ยท Neostigmine antagonizes their effect (therapeutic use) ยท major
- Atropine ยท Antagonizes the muscarinic effects of neostigmine (used therapeutically to manage side effects) ยท moderate
๋ชจ๋ํฐ๋ง
- Heart rate and rhythm (ECG monitoring recommended during IV administration)
- Respiratory rate, effort, and airway patency
- Signs of cholinergic crisis (excessive salivation, urination, defecation, miosis)
- Muscle strength and fasciculations
๊ณผ์ฉ๋
**Cholinergic Crisis** can occur with overdosage, presenting with both muscarinic and nicotinic effects (SLUDGE signs: Salivation, Lacrimation, Urination, Defecation, Gastrointestinal distress, Emesis), miosis, bradycardia, hypotension, muscle cramps, fasciculations, weakness, paralysis, bronchoconstriction, ataxia, seizures, and coma. **Management:** * **Maintenance of respiration** is the absolute priority. * Administer **Atropine** to control muscarinic signs (note: atropine does *not* antagonize nicotinic effects like muscle weakness and paralysis). * If muscle twitching is severe, control with small doses of a **competitive neuromuscular blocker**. * The cholinesterase reactivator **pralidoxime** can be used as an adjunct to atropine. * Provide intensive supportive care as required.
VetSheet ์ฝ๋ฌผ ๋ ํผ๋ฐ์ค๋ ๋ฉดํ ์์ ์ ๋ฌธ๊ฐ๋ฅผ ์ํ ์์ ์์ฌ๊ฒฐ์ ๋ณด์กฐ ๋๊ตฌ์ด๋ฉฐ, ์ ๋ฌธ์ ํ๋จ์ด๋ ์ ์กฐ์ฌ์ ์ต์ ๋ผ๋ฒจ์ ๋์ ํ์ง ์์ต๋๋ค.